Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
7.3.2023 15:00:00 EET | Business Wire | Press release
Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.
Under the collaboration, Charité will evaluate the potential of Exscientia’s precision medicine platform to select better treatments and improve outcomes for patients with haematological cancers. Each patient sample will be prospectively evaluated with a broad panel of marketed drugs, including drugs that may not yet be approved for the indication, to determine a comparative response profile, ex vivo.
“Despite major advances in the treatment of haematological cancers, the mortality rate for patients suffering from these conditions remains high. Following the results of the EXALT-1 trial, we believe that this new collaboration with Exscientia may present an opportunity to continue exploring how to meaningfully improve therapy selection and patient outcomes. Simultaneously, it is imperative that we develop a new generation of therapeutics against unexplored targets and biomarkers to improve patient outcomes, and we believe that our newly established biobank will enable Exscientia to move towards this goal,” said Prof. Ulrich Keller, M.D., Director Medical Department, Division of Haematology and Oncology at Charité.
This collaboration will expand on the results of the EXALT-1 study, which were previously published in the peer reviewed journal Cancer Discovery. EXALT-1 was a first-of-its-kind prospective trial, which demonstrated significantly improved outcomes for late-stage haematological cancer patients using Exscientia's deep learning-based high content functional drug testing platform to guide personalised treatment recommendations as compared to physician’s choice of treatment. A post-hoc analysis published in Blood Cancer Discovery showed that combining this technology with new deep learning advancements leveraging cell-specific features in high-content images had the potential to further improve patient outcomes.
Charité will also establish a biobank of viably cryopreserved blood, bone marrow and lymph node tissues to support further technology development and preclinical research projects at both Exscientia and Charité. Unlike conventional biobanks that typically contain dead specimens, this will contain live human tissue samples and therefore be instrumental for clinical and translational research.
“We are really excited to work with Charité to further advance the development and capabilities of our AI-driven functional precision medicine platform. Following the success of the EXALT-1 trial, we believe that AI-guided treatment has the potential to significantly improve patient outcomes, as well as healthcare economics, and we look forward to Charité using this approach in a clinical research setting,” said Professor Andrew Hopkins, D.Phil, Founder and CEO of Exscientia. "Charité’s work will contribute to Exscientia's growing body of evidence supporting our platform's potential in identifying the right treatment for the right patient. The systematic collection of viable tissue will allow us to further develop the technology as well as advance our clinical and future translational research around novel and better drugs as we seek to modernise the way we guide treatment selection for patients.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Charité – Universitätsmedizin Berlin
Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe, boasting 3,277 beds and approximately 100 departments and institutes spread across 4 separate campuses. At Charité, the areas of research, teaching and medical care are closely interlinked. With more than 21,000 members of staff employed across its group of companies, the organization is one of the largest employers in Berlin. In 2021 Charité treated 123,793 in- and day case patients, in addition to 682,731 outpatients. Charité recorded a turnover of approximately € 2.3 billion (including external funding and investment grants) and set a new record by securing more than € 215.8 million in external funding. Charité’s Medical Faculty is one of the largest in Germany, educating and training more than 9,000 students across the subjects of medicine, dentistry, health sciences and nursing. Charité also offers 730 training positions across 11 different health care professions, in addition to 111 training positions in a further 8 professions. Within the field of academic medicine, Charité’s priorities are highlighted by its main areas of research focus: infection; inflammation and immunity including COVID-19 research; cardiovascular research and metabolism; neuroscience; oncology; regenerative therapies; and rare diseases and genetics.
Exscientia Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, the development of Exscientia’s technology platform, and the progress and success of Exscientia’s strategic partnership with Charité, including the establishment of Charité’s biobank. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company’s business, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005070/en/
Contact information
Exscientia Investor Relations Contact:
Sara Sherman
investors@exscientia.ai
Exscientia Media Contact:
Oliver Stohlmann
media@exscientia.ai
Charité Media Relations Contact:
presse@charite.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization18.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced an expanded strategic partnership with American Digital Corporation to give SAP licensees a lower-risk, more flexible path to cloud modernization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118330258/en/ Rimini Street and American Digital Expand Partnership to Give SAP Licensees Greater Control Over Cloud Modernization Through the expanded relationship, American Digital will serve as a solution partner for Rimini Cloud™ for SAP, helping SAP ECC and S/4HANA licensees move their existing SAP systems to modern cloud infrastructure without requiring ERP reimplementation or conversion of perpetual licenses to subscriptions, while maintaining greater control over their long-term roadmap. The announcement builds on a strategic alliance establish
Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 16:00:00 EET | Press release
Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118877583/en/ Sila, a leading battery technology and materials company, today announced a comm
Two Cessna SkyCourier Aircraft Enter Aero-Medical Service With Delivery to Tassili Travail Aérien18.11.2026 16:00:00 EET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced it has delivered two Cessna SkyCourier aircraft equipped for aero-medical missions to Tassili Travail Aérien (TTA) of Algeria. The aircraft are the first aero-medical SkyCouriers in Africa and the first customer SkyCouriers to enter service on the continent, expanding the aircraft’s global presence and demonstrating its versatility for critical special missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015092210/en/ Textron Aviation completes delivery of Africa’s first two aero-medical equipped Cessna SkyCourier aircraft to Tassili Travail Aérien, also marking the first SkyCourier deliveries in Africa, expanding the aircraft’s special-mission capabilities. The two aircraft will support TTA’s passenger transportation and aero-medical evacuation operations serving Algeria’s energy sector. Equipped with the LifePort PLUS Powered Medevac System,
KŌZĒ Stays Launches International Expansion with More Than 1,200 Properties18.11.2026 15:28:00 EET | Press release
KŌZĒ Stays announces a major international expansion, bringing its curated portfolio to more than 1,200 properties worldwide. Following eight consecutive years of rapid growth, the company is building on its established presence in Mont-Tremblant and the Laurentians to pursue a broader ambition in international hospitality. The expanded collection spans French and Swiss alpine chalets, Riviera villas near Monaco, Lake Como residences, private retreats in St. Barths and homes on Dubai’s Palm Jumeirah. Available through The KŌZĒ Collection, these properties extend the brand’s reach into some of the world’s most sought-after destinations. Canadian Roots, International Ambition “A guest who loves their stay with us in Mont-Tremblant should be able to book their next trip, whether that’s Verbier, St. Barths or Lake Como, knowing the KŌZĒ standard travels with them,” said Jeffery Khoury, Founder and CEO of KŌZĒ Stays. “That’s what this expansion is about: one name you trust, wherever you tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
